Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-01-25
1997-09-02
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241931, 42419711, 4242771, 530300, 530328, 530403, A61K 3939, C07K 700
Patent
active
056629079
ABSTRACT:
The present invention relates to compositions and methods for treating cancer. The invention provides peptides based on a 9 residue epitope derived from the product of the tumor-associated gene MAGE-3. The peptide induces CTL that kill melanoma and other tumor cells lines.
REFERENCES:
patent: 5200320 (1993-04-01), Sette et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
Celis, E., et al., P.N.A.S. (USA) 91:2105-2109 (Mar., 1994), "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary culture and synthetic peptide epitopes".
Ding, M., et al., Biochem. Biophys. Res. Comm. 202(1) 549-555 (Jul. 15, 1994), "Cloning and analysis of MAGE-1-related genes".
Gaugler, B., et al., J. Exp. Med. 179(3):921-930 (Mar. 1, 1994), "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes".
Oaks, M. K., et al., Cancer Res. 54: 1627-29 (Apr. 1, 1994), "Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qter: implications for MAGE immunotherapy".
Paul, W. F. (ed.), Fundamental Immunology, 3rd edition, pp. 976-978 (1993), Raven Press, New York.
Traversari, C., et al., J. Exp. Med. 176:1453-1457 (Nov., 1992), "A nonpeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2E".
Robbins Pathologic Basis of Disease, 4th edition (R.S. Cotran, et al., ed.), pp. 296-299 (1989), W.B. Saunders Co., Philadelphia.
Weynants, P., et al., Int. J. Cancer 56:826-29 (1994), "Expression of MAGE genes by non-small-cell lung carcinomas".
Zakut, R., et al., Cancer Res. 53:5-8 (Jan. 1, 1993), "Differential expression of MAGE-1, -2 and -3 messenger RNA in transformed and normal human cell lines".
Aichele, P et al., J. Exp. Med. 171:1815-1820 (May, 1990), "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide". May 1990.
Kast, W. M. et al., Proc. Nat'l Acad. Sci. 88:2283-2287 (Mar., 1991), "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide". Mar. 1991.
Deres, K. et al., Nature 342:561-564 (30 Nov. 1989), "In vivo priming of virus-specific cytotoxic lymphocytes with synthetic lipopeptide vaccine". Nov. 30, 1989.
Traversari, C. et al., J. Exp. Med. 176:1453-1457 (Nov., 1992), "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E". Nov. 1992.
Celis Esteban
Grey Howard M.
Kubo Ralph T.
Sette Alessandro
Cunningham Thomas M.
Cytel Corporation
LandOfFree
Induction of anti-tumor cytotoxic T lymphocytes in humans using does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of anti-tumor cytotoxic T lymphocytes in humans using , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of anti-tumor cytotoxic T lymphocytes in humans using will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-306104